Scynexis Q2 2022 Earnings Report

BREXAFEMME net revenues were $1.3 million in Q2 2022, compared to $0.7 million in Q1 2022.

SCYNEXIS filed a supplemental New Drug Application (sNDA) to expand BREXAFEMME’s labelling to include the prevention of recurrent vulvovaginal candidiasis (RVVC); the FDA assigned a target PDUFA action date of November 30, 2022 for this additional indication.

Enrollment has begun in two global Phase 3 trials: the MARIO study and the VANQUISH study.

Based on a cash balance of $118.7 million at June 30, 2022, SCYNEXIS has a projected cash runway into Q1 2024.